Home Health & Hospice Week

Know Your Facts:

Publicly Traded Companies Changed Therapy Utilization In Response To Reimbursement

One chain saw 10-therapy-visit episodes drop from 20 to 7 percent in one year. Law- and policymakers likely soon will decide how to reconfigure the home health prospective payment system in light of alleged abuses of therapy utilization. Take a look at the statistics they will use to inform the decision. The Senate Finance Committee uncovered these figures when investigating publicly traded home health companies' alleged improprieties regarding therapy utilization: At Baton Rouge, La.-based Amedisys Inc., the percent of the company's therapy episodes with 10 visits went from 9.1 percent in 2007 to 4.9 percent in 2008, the report says. "Also from 2007 to 2008, the number of therapy episodes receiving 6 visits increased from 4.6 percent to 5.3 percent, and the number of therapy episodes receiving 14 visits increased from 4.7 percent to 5.8 percent." Amedisys' home health episodes with therapy reimbursement accounted for 71 percent of Medicare revenue [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Home Health & Hospice Week

View All